SEC Company Response from SciSparc Ltd. (SPRC) (CIK 0001611746) (SPRC) — Mar 20, 2017
SciSparc Ltd. (SPRC) (CIK 0001611746)
Date: March 20, 2017 · CIK: 0001611746 · Accession: 0001213900-17-002575
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-214458
Letter
Via EDGAR Office of Healthcare and Insurance Securities and Exchange Commission Amendment No.7 to Registration Statement on Form F-1 Filed March 15, 2017 File No. 333-214458 CIK No. 0001611746
Dear Ms. Hayes:
The purpose of this letter is to respond to your letter of March 17, 2017, regarding the abovementioned registration statement. For your convenience, your original comments appear in bold text, followed by our response. On March 20, 2017, we filed Amendment No. 8 to our registration statement on Form F-1. Page references in our responses are to the Amendment No. 8 to Form F-1.
Cover Page
1. We refer to your revised offering size and your revised price range. Please update the fee table to correspond to the new proposed maximum offering amount.
Response: We have revised the fee table accordingly.
Business
Other Indications, page 53
2. We refer to the press release on your website indicating that you have entered into a MOU with Rafa Laboratories to form a joint venture to research and develop a drug for certain indications, and that both you and Rafa will invest seed capital in this venture. Please update your disclosure to provide information regarding the MOU, or alternatively, explain the basis for your belief that the MOU is not material.
Response: We have revised our disclosure on page 53.
If you have any questions or require additional information, please call our attorneys, Howard Berkenblit at (617) 338-2979 or Oded Har-Even at (212) 660-5002, of Zysman, Aharoni, Gayer and Sullivan & Worcester LLP.
Sincerely,
THERAPIX
BIOSCIENCES LTD.
Show Raw Text
CORRESP
1
filename1.htm
Therapix
biosciences ltd.
5
Azrieli Center (Square Tower)
Tel
Aviv, 6702501 Israel
March
20, 2017
Via
EDGAR
Suzanne
Hayes, Assistant Director
Office
of Healthcare and Insurance
Securities
and Exchange Commission
100
F Street, NE
Washington,
DC 20549
Re:
Therapix
Biosciences Ltd.
Amendment
No.7 to Registration Statement on Form F-1
Filed
March 15, 2017
File
No. 333-214458
CIK
No. 0001611746
Dear
Ms. Hayes:
The
purpose of this letter is to respond to your letter of March 17, 2017, regarding the abovementioned registration statement. For
your convenience, your original comments appear in bold text, followed by our response. On March 20, 2017, we filed Amendment
No. 8 to our registration statement on Form F-1. Page references in our responses are to the Amendment No. 8 to Form F-1.
Cover
Page
1. We
refer to your revised offering size and your revised price range. Please update the fee table to correspond to the new proposed
maximum offering amount.
Response:
We have revised the fee table accordingly.
Business
Other
Indications, page 53
2. We
refer to the press release on your website indicating that you have entered into a MOU with Rafa Laboratories to form a joint
venture to research and develop a drug for certain indications, and that both you and Rafa will invest seed capital in this venture.
Please update your disclosure to provide information regarding the MOU, or alternatively, explain the basis for your belief that
the MOU is not material.
Response:
We have revised our disclosure on page 53.
If
you have any questions or require additional information, please call our attorneys, Howard Berkenblit at (617) 338-2979 or Oded
Har-Even at (212) 660-5002, of Zysman, Aharoni, Gayer and Sullivan & Worcester LLP.
Sincerely,
THERAPIX
BIOSCIENCES LTD.
By:
/s/
Dr. Elran Haber
Chief
Executive Officer